Rigel is committed to advancing the knowledge of our therapies and therapeutic areas of interest.
Rigel considers requests for study drug and/or monetary grants for independent, investigator sponsored research that meet both our scientific and medical criteria.
Proposed studies will be assessed based on scientific merit, validity and rigor of the study, risk/benefit assessment to ensure the safety of human subjects, consistency with Rigel’s values, and other scientific and medical considerations.
Please contact IST@rigel.com for further information and instructions to apply using our Concept Submission Form.
Areas of Research Interests:
Olutasidenib
- Explore the use of olutasidenib to overcome resistance mechanisms from frontline therapies in relapsed/refractory mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML)
- Better understand olutasidenib sequencing strategies to optimize treatment outcomes in relapsed/refractory mIDH1 AML
- Explore the use of olutasidenib in combination with other targeted therapies in newly diagnosed or relapsed/refractory mIDH1 AML
- Explore the use of olutasidenib (monotherapy or in combination) in other disease states where IDH1 mutations are targetable (e.g., chondrosarcoma, cholangiocarcinoma)
Fostamatinib*
- Explore the use of fostamatinib in combination with other agents for the treatment of chronic immune thrombocytopenia (ITP)
- Explore the use of fostamatinib in post-pubescent pediatric patients with growth plate closure in chronic ITP
- Explore the use of fostamatinib in other disease states driven by spleen tyrosine kinase (SYK)-mediated mechanisms
Pralsetinib
- Pralsetinib areas of research interests are currently under development
*Research Grants supporting fostamatinib will be considered for study drug only